Feb 12 (Reuters) - Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems. The company also reiterated its 2026 revenue forecast of $5.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.

Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," focusing on improving sensor accuracy and reliability;

DexCom (NASDAQ: DXCM) is gearing up to announce its quarterly earnings on Thursday, 2026-02-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that DexCom will report an earnings per share (EPS) of $0.65.

Analysts expect DexCom to report earnings of $0.6459 per share on revenue of $1.24 billion for the quarter ended December 2025. That would mark a sequential improvement from the third quarter’s $0.61 per share and $1.21 billion in revenue, representing modest gains of 5.9% and 2.5% respectively.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates

DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its longer term growth plans.

Diabetes is a disease in which there is too much sugar in a person's blood. Type 2 diabetes is most common and is caused by factors such as obesity or lack of exercise. Rising obesity rates are a big reason why more people are being diagnosed with diabetes ...

Ed Gamble and Roxy Horner, who live with Type 1 diabetes, at the Dexcom's "No Pricks Parlour" vintage ice cream truck, handing out free ice cream on London's South Bank to celebrate Diabetes Awareness Week. Picture date: Tuesday June 14, 2022. (Photo by ...

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.